Evaluation of bleeding adverse events associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system
P2Y12 inhibitors show different bleeding-related safety profiles in premarketing trials. However, little is known about their potential safety from spontaneous reporting systems and postmarketing data. To describe and evaluate the bleeding-related adverse events associated with use of P2Y12 inhibito...
Saved in:
Published in | International journal of clinical pharmacology and therapeutics |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Germany
10.02.2019
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!